ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by reducing bradykinin production, potentially offering better and less frequent treatment than current options. The presentation will also cover the ongoing Phase 3 STOP-HAE trial, which aims to confirm these benefits. This therapy has received Orphan Drug Designation from the FDA, highlighting its potential to improve HAE management.
Ormat Technologies introduced the Ormega100, the industry's largest binary power generation unit delivering 100 MW output, designed to accelerate commercialization and scaling of Enhanced Geothermal Systems (EGS). With 60 years of expertise and exten...
FDH Aero, a leading aerospace and defense supply chain provider, has agreed to a majority investment from Bain Capital Private Equity, with Audax Private Equity remaining a significant investor. This partnership aims to accelerate FDH's growth strate...
Cyabra, an AI-driven disinformation intelligence company, has secured a contract worth over $500,000 to provide its technology to a leading international research institute focused on tracking global hate speech. The platform will help identify coord...
Novo Nordisk announced positive Phase 3 trial results for CagriSema, a once-weekly therapy combining an amylin analog with a GLP-1 receptor agonist, which significantly reduced HbA1c and body weight in adults with Type 2 diabetes. The company also sh...
Hyperscale Data's stock surged 23.18% in premarket trading driven by a broader market rally and increased risk appetite among investors. The company reported holding 704.34 Bitcoin, valued at about $51.8 million as of May 31, 2026, reinforcing its di...
